Drug Profile


Alternative Names: R 64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.
  • Developer Alkermes; Janssen; Janssen L.P.; Janssen Pharmaceutical KK; Janssen-Cilag
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aggression; Autistic disorder; Bipolar disorders; Dementia; Schizophrenia
  • No development reported Anxiety disorders; Drug abuse; Major depressive disorder; Obsessive-compulsive disorders
  • Discontinued Gilles de la Tourette's syndrome

Most Recent Events

  • 14 Jul 2017 Xian-Janssen plans a phase I bioequivalence trial in Healthy volunteers in China (PO) (NCT03220867)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in USA (IM, Controlled release)
  • 25 Feb 2016 Alkermes has patent protection for the microsphere technology in USA and Europe (Alkermes, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top